Familial nodular lymphocyte predominant Hodgkin lymphoma: Successful treatment with CHOP plus rituximab

Leukemia and Lymphoma

Volumn 46, Issue 11, 2005, Pages 1613-1617

  Unal, A ^a   Sari, Ismail ^a   Deniz, K ^a   Ozkan, M ^a   Kontas, O ^a   Eser, B ^a   Cetin, M ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

CHOP; Familial Hodgkin lymphoma; Nodular lymphocyte predominant Hodgkin lymphoma; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CASE REPORT; DRUG TOLERABILITY; FAMILIAL CANCER; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; MALE; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; PRIORITY JOURNAL; RARE DISEASE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FAMILY HEALTH; FEMALE; HODGKIN DISEASE; HUMANS; LYMPH NODES; LYMPHOCYTES; MALE; MIDDLE AGED; PREDNISOLONE; REMISSION INDUCTION; VINCRISTINE;

EID: 28244450242     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500236502     Document Type: Article

References (24)

1. Shpilberg G, Modan M, Modan B, Chetrit A, Fuchs Z, Ramot B. Familial aggregation of hematological neoplasms: a controlled study. Br J Haematol 1994;87:75-80.
2. Greene MH, Brinton LA, Fraumeni JJ, D'Amico R. Familial and sporadic Hodgkin's disease associated with occupational wood exposure. Lancet 1978;2:626-627.
3. Haim N, Cohen Y, Robinson E. Malignant lymphoma in first-degree blood relatives. Cancer 1982;49:2197-2200.
4. Kerzin-Storrar L, Faed MJW, MacGillivray JB, Smith PG. Incidence of familial Hodgkin's disease. Br J Cancer 1983;47:707-712.
5. Mack TM, Cozen W, Shibata DK, Weiss LM, Nathwani BN, Hernandez AM et al. Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med 1995;332:413-418.
6. Greene MH, McKeenn EZ, Li FP, Blattner WA, Fraumeni JF. HLA antigens in familial Hodgkin's Disease. Int J Cancer 1979;23:777-780.
7. Hors J, Daussel J. HLA and susceptibility to Hodgkin's disease. Immunol Rev 1983;70:167-192.
8. Harty LC, Lin AY, Goldstein AM, Juffe ES, Currington M, Tucker MA, et al. HLA-DR, HLA-DQ and TAP genes in familial Hodgkin's disease. Blood 2002;99:690-693.
9. Grufferman S, Delzell E. Epidemiology of Hodgkin's disease. Epidemiol Rev 1984;6:76-106.
10. Campbell GN, Lloyd J, Wotherspoon A, Coulter C, Bain BJ. Nodular lymphocyte predominant Hodgkin lymphoma in siblings. Leuk Lymphoma 2004;45:609-611.
11. Colby T, Hoppe R, Warnke R. Hodgkin's disease: a clinicopathologic study of 659 cases. Cancer 1982;49:1848-1858.
12. Tubiana M, Henry-Amar M, Carde P. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood 1989;73:47-56.
13. Schlembach PJ, Wilder RB, Jones D, Ha CS, Fayad LE, Younes A, et al. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. Cancer J 2002;8:377-383.
14. Miettinen M, Franssila KO, Saxen E. Hodgkin's disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin's lymphomas. Cancer J 1983;51: 2293-2300.
15. Diehl V, Sextro M, Franklin J, Hansmann ML, Harris N, Jaffe E, Poppema S. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 1999;17:776-783.
16. Chittal SM, Brousset P, Voigt JJ, Delsol G. Large B-cell lymphoma rich in T-cells and simulating Hodgkin's disease. Histopathology 1991;19:211-220.
17. Kielholz U, Szelenya H, Siehl J, Foss HD, Knauf W, Thiel E. Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD20 monoclonal antibody) and interleukin-2. Leuk Lymphoma 1999;35:641-642.
18. Lush RJ, Jones SG, Haynes AP. Advanced-stage, chemorefractory lymphocyte-predominant Hodgkin's disease: long-term follow-up of allografting and monoclonal antibody therapy. Br J Haematol 2001;114:734-735.
19. Rehwald U, Schulz H, Reiser M, Sieber M, Staak JO, Morschhauser F, et al. German Hodgkin Lymphoma Study Group (GHSG). Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma. Study Group. Blood 2003;101: 420-424.
20. Ekstrand BC, Lucas JB, Horwitz SM, Fan Z, Breslin S, Hoppe RT, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 2003;101: 4285-4289.
21. Ramsay AD, Smith WJ, Isaacson PG. T-cell-rich-B-cell lymphoma. Am J Surg Pathol 1988;12:433-443.
22. Delabie J, Vandenberghe E, Kennes C, Verhoef G, Foschini MP, Stul M, et al. Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype. Am J Surg Pathol 1992;16:37-48.
23. De Jong D, Van Gorp J, Sie-Go D, Van Heerde P. T-cell rich B-cell non-Hodgkin's lymphoma: a progressed form of follicle centre cell lymphoma and lymphocyte predominance Hodgkin's disease. Histopathology 1996;28:15-24.
24. McBride JA, Rodriguez J, Luthra R, Ordonez NG, Cabanillas F, Pugh WC. T-cell-rich B large-cell lymphoma simulating lymphocyte-rich Hodgkin's disease. Am J Surg Pathol 1996;20:193-201.